Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...
TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $30 from $24 and keeps a Buy rating on the shares. The firm said Q4 ...
Intra-Cellular Therapies, Inc. Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023. Full year 2024 CAPLY ...